Dupuytren's Disease
Conditions
Brief summary
Experience with Microbial Collagenase (trade name Xiapex) in Europe currently is limited to randomised controlled studies.While such studies are essential to determine efficacy and safety of the product (usually compared to placebo), they provide no information on the effectiveness of the drug and further aspects of its use (feasibility, tolerability, quality of life and other patient-related outcomes) in the typical real-life setting under clinical practice conditions.Thus, the present study aims to collect data on the * Drug utilization of Microbial Collagenase in the hand of physicians, with focus on feasibility, treatment patterns, and effectiveness in clinical practice * Context of Microbial Collagenase therapy (setting, patient characteristics, concomitant treatment, follow-up therapy) * Effectiveness (with focus on functionality) * Tolerability * Patient-related outcomes: patient satisfaction, health-related quality of life * Physician satisfaction with therapy * Resource utilization (hospital stays, drug consumption, concomitant medication etc.) * Long-term outcomes
Interventions
None listed
Sponsors
GWT-TUD GmbH
Pfizer
Technische Universität Dresden
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* palpable cord due to Dupuytren's Disease (pretreated or untreated) * satisfactory knowledge of German to be able to fill out questionnaires * written informed consent
Exclusion criteria
* contraindication to Microbial Collagenase (according to Prescription Information)
Countries
Germany
Outcome results
None listed